Methylphenidate Hydrochloride Patent Expiration
Methylphenidate Hydrochloride was first introduced by Sandoz Inc
Methylphenidate Hydrochloride Patents
Given below is the list of patents protecting Methylphenidate Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Adhansia Xr | US10111839 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US10292938 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US10292939 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US10449159 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US10500162 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US10507186 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US10512612 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US10512613 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US10568841 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US10688060 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Adhansia Xr | US10722473 | Methods and compositions particularly for treatment of attention deficit disorder | Nov 19, 2038 | Purdue Pharma Lp |
| Adhansia Xr | US9974752 | Methods and compositions particularly for treatment of attention deficit disorder | Oct 30, 2035 | Purdue Pharma Lp |
| Aptensio Xr | US10039719 | Methods of treating attention deficit hyperactivity disorder |
Dec 16, 2019
(Expired) | Rhodes Pharms |
| Aptensio Xr |
US10039719 (Pediatric) | Methods of treating attention deficit hyperactivity disorder |
Jun 16, 2020
(Expired) | Rhodes Pharms |
| Aptensio Xr | US10463624 | Controlled release formulations |
Dec 16, 2019
(Expired) | Rhodes Pharms |
| Aptensio Xr | US6419960 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec 16, 2019
(Expired) | Rhodes Pharms |
| Aptensio Xr |
US6419960 (Pediatric) | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun 16, 2020
(Expired) | Rhodes Pharms |
| Aptensio Xr | US7083808 | Controlled/modified release oral methylphenidate formulations |
Dec 16, 2019
(Expired) | Rhodes Pharms |
| Aptensio Xr |
US7083808 (Pediatric) | Controlled/modified release oral methylphenidate formulations |
Jun 16, 2020
(Expired) | Rhodes Pharms |
| Aptensio Xr | US7247318 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec 16, 2019
(Expired) | Rhodes Pharms |
| Aptensio Xr |
US7247318 (Pediatric) | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun 16, 2020
(Expired) | Rhodes Pharms |
| Aptensio Xr | US7438930 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec 16, 2019
(Expired) | Rhodes Pharms |
| Aptensio Xr |
US7438930 (Pediatric) | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun 16, 2020
(Expired) | Rhodes Pharms |
| Aptensio Xr | US8580310 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec 16, 2019
(Expired) | Rhodes Pharms |
| Aptensio Xr |
US8580310 (Pediatric) | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun 16, 2020
(Expired) | Rhodes Pharms |
| Aptensio Xr | US9066869 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec 16, 2019
(Expired) | Rhodes Pharms |
| Aptensio Xr |
US9066869 (Pediatric) | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun 16, 2020
(Expired) | Rhodes Pharms |
| Aptensio Xr | US9801823 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec 16, 2019
(Expired) | Rhodes Pharms |
| Aptensio Xr |
US9801823 (Pediatric) | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun 16, 2020
(Expired) | Rhodes Pharms |
| Concerta | US6919373 | Methods and devices for providing prolonged drug therapy |
Jul 31, 2017
(Expired) | Janssen Pharms |
| Concerta |
US6919373 (Pediatric) | Methods and devices for providing prolonged drug therapy |
Jan 31, 2018
(Expired) | Janssen Pharms |
| Concerta | US6930129 | Methods and devices for providing prolonged drug therapy |
Jul 31, 2017
(Expired) | Janssen Pharms |
| Concerta |
US6930129 (Pediatric) | Methods and devices for providing prolonged drug therapy |
Jan 31, 2018
(Expired) | Janssen Pharms |
| Concerta | US8163798 | Methods and devices for providing prolonged drug therapy |
Jul 31, 2017
(Expired) | Janssen Pharms |
| Concerta |
US8163798 (Pediatric) | Methods and devices for providing prolonged drug therapy |
Jan 31, 2018
(Expired) | Janssen Pharms |
| Concerta | US8629179 | Methods and devices for providing prolonged drug therapy |
Jul 31, 2017
(Expired) | Janssen Pharms |
| Concerta |
US8629179 (Pediatric) | Methods and devices for providing prolonged drug therapy |
Jan 31, 2018
(Expired) | Janssen Pharms |
| Concerta | US9000038 | Methods and devices for providing prolonged drug therapy |
Jul 31, 2017
(Expired) | Janssen Pharms |
| Concerta |
US9000038 (Pediatric) | Methods and devices for providing prolonged drug therapy |
Jan 31, 2018
(Expired) | Janssen Pharms |
| Concerta | US9029416 | Methods and devices for providing prolonged drug therapy |
Jul 31, 2017
(Expired) | Janssen Pharms |
| Concerta | US9144549 | Methods and devices for providing prolonged drug therapy |
Jul 31, 2017
(Expired) | Janssen Pharms |
| Jornay Pm | US10182995 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US10292937 | Methods of treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US10617651 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US10881618 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US10905652 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US11241391 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US11241392 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US11911518 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US8916588 | Methods for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US8927010 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US9023389 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US9028868 | Methods and compositions for treatment of attention deficit disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US9034902 | Methods for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US9283214 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US9498447 | Compositions for treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Jornay Pm | US9603809 | Methods of treatment of attention deficit hyperactivity disorder | Mar 23, 2032 | Ironshore Pharms |
| Metadate Cd | US6344215 | Methylphenidate modified release formulations |
Oct 27, 2020
(Expired) | Aytu Biopharma |
| Methylin | US7691880 | Methylphenidate solution and associated methods of administration and production | Oct 07, 2024 | Specgx Llc |
| Quillichew Er | US10857143 | Methylphenidate extended release chewable tablet | Aug 14, 2033 | Nextwave Pharms |
| Quillichew Er | US11103494 | Methylphenidate extended release chewable tablet | Aug 14, 2033 | Nextwave Pharms |
| Quillichew Er | US11103495 | Methylphenidate extended release chewable tablet | Aug 14, 2033 | Nextwave Pharms |
| Quillichew Er | US11633389 | Methylphenidate extended release chewable tablet | Aug 14, 2033 | Nextwave Pharms |
| Quillichew Er | US8202537 | Modified release formulations containing drug-ion exchange resin complexes | Mar 15, 2027 | Nextwave Pharms |
| Quillichew Er | US8287903 | Orally effective methylphenidate extended release powder and aqueous suspension product | Feb 15, 2031 | Nextwave Pharms |
| Quillichew Er | US8999386 | Methylphenidate extended release chewable tablet | Aug 14, 2033 | Nextwave Pharms |
| Quillichew Er | US9295642 | Methylphenidate extended release chewable tablet | Aug 14, 2033 | Nextwave Pharms |
| Quillichew Er | US9545399 | Methylphenidate extended release chewable tablet | Aug 14, 2033 | Nextwave Pharms |
| Quillichew Er | US9844544 | Methylphenidate extended release chewable tablet | Aug 14, 2033 | Nextwave Pharms |
| Quillivant Xr | US8062667 | Modified release formulations containing drug-ion exchange resin complexes | Mar 29, 2029 | Nextwave |
| Quillivant Xr | US8287903 | Orally effective methylphenidate extended release powder and aqueous suspension product | Feb 15, 2031 | Nextwave |
| Quillivant Xr | US8465765 | Orally effective methylphenidate extended release powder and aqueous suspension product | Feb 15, 2031 | Nextwave |
| Quillivant Xr | US8563033 | Orally effective methylphenidate extended release powder and aqueous suspension product | Feb 15, 2031 | Nextwave |
| Quillivant Xr | US8778390 | Orally effective methylphenidate extended release powder and aqueous suspension product | Feb 15, 2031 | Nextwave |
| Quillivant Xr | US8956649 | Orally effective methylphenidate extended release powder and aqueous suspension product | Feb 15, 2031 | Nextwave |
| Quillivant Xr | US9040083 | Orally effective methylphenidate extended release powder and aqueous suspension product | Feb 15, 2031 | Nextwave |
| Ritalin La | US5837284 | Delivery of multiple doses of medications |
Dec 04, 2015
(Expired) | Sandoz |
| Ritalin La | US6228398 | Multiparticulate modified release composition |
Nov 01, 2019
(Expired) | Sandoz |
| Ritalin La | US6635284 | Delivery of multiple doses of medications |
Dec 04, 2015
(Expired) | Sandoz |
| Ritalin La | US7431944 | Delivery of multiple doses of medications |
Dec 04, 2015
(Expired) | Sandoz |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Methylphenidate Hydrochloride's patents.
Latest Legal Activities on Methylphenidate Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Methylphenidate Hydrochloride.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jun, 2024 | US9545399 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 May, 2024 | US10857143 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 03 Apr, 2024 | US8287903(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Dec, 2023 | US8202537(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Sep, 2023 | US9295642 |
| Mail Miscellaneous Communication to Applicant | 27 Apr, 2023 | US11633389 |
| Electronic Review | 27 Apr, 2023 | US11633389 |
| Email Notification | 27 Apr, 2023 | US11633389 |
| Miscellaneous Communication to Applicant - No Action Count | 25 Apr, 2023 | US11633389 |
| Patent Issue Date Used in PTA Calculation | 25 Apr, 2023 | US11633389 |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Methylphenidate Hydrochloride Generics
Several generic applications have been filed for Methylphenidate Hydrochloride. The first generic version for Methylphenidate Hydrochloride was by Lannett Co Inc and was approved on Approved Prior to Jan 1, 1982. And the latest generic version is by Sun Pharmaceutical Industries Inc and was approved on Aug 25, 2023.
Given below is the list of companies who have filed for Methylphenidate Hydrochloride generic.
1. OXFORD PHARMS
Oxford Pharmaceuticals Llc has filed for 3 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Oxford Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 20MG | tablet | Prescription | ORAL | AB | Sep 23, 2014 |
| 5MG | tablet | Prescription | ORAL | AB | Sep 23, 2014 |
| 10MG | tablet | Prescription | ORAL | AB | Sep 23, 2014 |
2. HERITAGE PHARMA
Heritage Pharma Labs Inc has filed for 1 generic for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Heritage Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 20MG | tablet, extended release | Discontinued | ORAL | N/A | Dec 21, 2001 |
3. AUROLIFE PHARMA LLC
Aurolife Pharma Llc has filed for 7 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Aurolife Pharma Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 36MG | tablet, extended release | Prescription | ORAL | AB | Oct 21, 2016 |
| 54MG | tablet, extended release | Prescription | ORAL | AB | Oct 21, 2016 |
| 18MG | tablet, extended release | Prescription | ORAL | AB | Oct 21, 2016 |
| 27MG | tablet, extended release | Prescription | ORAL | AB | Oct 21, 2016 |
| 5MG | tablet | Discontinued | ORAL | N/A | Oct 25, 2018 |
| 10MG | tablet | Discontinued | ORAL | N/A | Oct 25, 2018 |
| 20MG | tablet | Discontinued | ORAL | N/A | Oct 25, 2018 |
4. NOSTRUM LABS INC
Nostrum Laboratories Inc has filed for 4 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Nostrum Labs Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet | Discontinued | ORAL | N/A | Mar 3, 2017 |
| 5MG | tablet | Discontinued | ORAL | N/A | Mar 3, 2017 |
| 2.5MG | tablet, chewable | Discontinued | ORAL | N/A | Jan 26, 2017 |
| 20MG | tablet | Discontinued | ORAL | N/A | Mar 3, 2017 |
5. LANNETT CO INC
Lannett Co Inc has filed for 7 different strengths of generic version for Methylphenidate Hydrochloride. Out of these 10mg version comes by the name METADATE ER, 20mg version comes by the name METADATE ER. Given below are the details of the strengths of this generic introduced by Lannett Co Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet, extended release | Discontinued | ORAL | N/A | Oct 20, 1999 |
| 20MG | tablet, extended release | Discontinued | ORAL | N/A | Jun 1, 1988 |
| 5MG | tablet | Discontinued | ORAL | N/A | Approved Prior to Jan 1, 1982 |
| 18MG | tablet, extended release | Prescription | ORAL | BX | Jul 9, 2013 |
| 27MG | tablet, extended release | Prescription | ORAL | BX | Jul 9, 2013 |
| 36MG | tablet, extended release | Prescription | ORAL | BX | Sep 23, 2013 |
| 54MG | tablet, extended release | Prescription | ORAL | BX | Sep 23, 2013 |
6. STRIDES PHARMA
Strides Pharma Global Pte Ltd has filed for 2 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Strides Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 54MG | tablet, extended release | Discontinued | ORAL | N/A | Jul 15, 2019 |
| 36MG | tablet, extended release | Discontinued | ORAL | N/A | Jul 15, 2019 |
7. AMNEAL PHARMS
Amneal Pharmaceuticals Of New York Llc has filed for 4 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Amneal Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 36MG | tablet, extended release | Discontinued | ORAL | N/A | Feb 1, 2018 |
| 18MG | tablet, extended release | Discontinued | ORAL | N/A | Feb 1, 2018 |
| 27MG | tablet, extended release | Discontinued | ORAL | N/A | Feb 1, 2018 |
| 54MG | tablet, extended release | Discontinued | ORAL | N/A | Feb 1, 2018 |
8. WES PHARMA INC
Wes Pharma Inc has filed for 2 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Wes Pharma Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG/5ML | solution | Prescription | ORAL | AA | Oct 3, 2018 |
| 10MG/5ML | solution | Prescription | ORAL | AA | Oct 3, 2018 |
9. ANDOR PHARMS
Andor Pharmaceuticals Llc has filed for 4 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Andor Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 36MG | tablet, extended release | Prescription | ORAL | AB | Apr 24, 2019 |
| 54MG | tablet, extended release | Prescription | ORAL | AB | Apr 24, 2019 |
| 27MG | tablet, extended release | Prescription | ORAL | AB | Apr 24, 2019 |
| 18MG | tablet, extended release | Prescription | ORAL | AB | Apr 24, 2019 |
10. OSMOTICA PHARM US
Osmotica Pharmaceutical Us Llc has filed for 5 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Osmotica Pharm Us.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 36MG | tablet, extended release | Prescription | ORAL | AB | Jul 28, 2017 |
| 72MG
(reference standard) | tablet, extended release | Prescription | ORAL | AB | Jul 28, 2017 |
| 54MG | tablet, extended release | Prescription | ORAL | AB | Jul 28, 2017 |
| 27MG | tablet, extended release | Prescription | ORAL | AB | Jul 28, 2017 |
| 18MG | tablet, extended release | Prescription | ORAL | AB | Jul 28, 2017 |
11. NOVEL LABS INC
Novel Laboratories Inc has filed for 6 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Novel Labs Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet | Prescription | ORAL | AB | Nov 13, 2015 |
| 2.5MG | tablet, chewable | Discontinued | ORAL | N/A | Feb 25, 2015 |
| 5MG | tablet | Prescription | ORAL | AB | Nov 13, 2015 |
| 5MG/5ML | solution | Prescription | ORAL | AA | Aug 14, 2015 |
| 10MG/5ML | solution | Prescription | ORAL | AA | Aug 14, 2015 |
| 20MG | tablet | Prescription | ORAL | AB | Nov 13, 2015 |
12. TRIS PHARMA INC
Tris Pharma Inc has filed for 2 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Tris Pharma Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG/5ML | solution | Prescription | ORAL | AA | Jul 23, 2010 |
| 5MG/5ML | solution | Prescription | ORAL | AA | Jul 23, 2010 |
13. SUN PHARM INDS INC
Sun Pharmaceutical Industries Inc has filed for 8 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Sun Pharm Inds Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 20MG | tablet | Prescription | ORAL | AB | Mar 15, 2012 |
| 5MG | tablet | Prescription | ORAL | AB | Mar 15, 2012 |
| 10MG | tablet | Prescription | ORAL | AB | Mar 15, 2012 |
| 36MG | tablet, extended release | Prescription | ORAL | AB | Aug 19, 2020 |
| 18MG | tablet, extended release | Prescription | ORAL | AB | Aug 19, 2020 |
| 27MG | tablet, extended release | Prescription | ORAL | AB | Aug 19, 2020 |
| 54MG | tablet, extended release | Prescription | ORAL | AB | Aug 19, 2020 |
| 72MG | tablet, extended release | Prescription | ORAL | AB | Aug 25, 2023 |
14. QUAGEN
Quagen Pharmaceuticals Llc has filed for 2 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Quagen.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG/5ML | solution | Prescription | ORAL | AA | Jun 4, 2020 |
| 5MG/5ML | solution | Prescription | ORAL | AA | Jun 4, 2020 |
15. PATRIN
Patrin Pharma Inc has filed for 2 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Patrin.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG/5ML | solution | Prescription | ORAL | AA | Apr 10, 2020 |
| 5MG/5ML | solution | Prescription | ORAL | AA | Apr 10, 2020 |
16. ABHAI LLC
Abhai Llc has filed for 4 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Abhai Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet, extended release | Prescription | ORAL | AB | Jun 9, 2015 |
| 20MG
(reference standard) | tablet, extended release | Prescription | ORAL | AB | Jun 9, 2015 |
| 5MG/5ML | solution | Prescription | ORAL | AA | Nov 18, 2016 |
| 10MG/5ML | solution | Prescription | ORAL | AA | Nov 18, 2016 |
17. ACTAVIS LABS FL
Actavis Laboratories Fl Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc has filed for 5 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Actavis Labs Fl.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 54MG | tablet, extended release | Prescription | ORAL | AB | Mar 21, 2018 |
| 36MG | tablet, extended release | Prescription | ORAL | AB | Mar 22, 2018 |
| 27MG | tablet, extended release | Prescription | ORAL | AB | Mar 22, 2018 |
| 18MG | tablet, extended release | Prescription | ORAL | AB | Mar 22, 2018 |
| 72MG | tablet, extended release | Prescription | ORAL | AB | Feb 28, 2022 |
18. WATSON LABS
Watson Laboratories Inc has filed for 3 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Watson Labs.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG | tablet | Discontinued | ORAL | N/A | Aug 29, 1997 |
| 10MG | tablet | Discontinued | ORAL | N/A | Aug 29, 1997 |
| 20MG | tablet, extended release | Discontinued | ORAL | N/A | Feb 9, 2001 |
19. DR REDDYS LABS SA
Dr Reddys Laboratories Sa has filed for 5 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Dr Reddys Labs Sa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG | capsule, extended release | Prescription | ORAL | AB1 | Dec 1, 2011 |
| 30MG | capsule, extended release | Prescription | ORAL | AB1 | Dec 1, 2011 |
| 20MG | capsule, extended release | Prescription | ORAL | AB1 | Dec 1, 2011 |
| 60MG
(reference standard) | capsule, extended release | Prescription | ORAL | AB1 | Jun 23, 2016 |
| 10MG | capsule, extended release | Prescription | ORAL | AB1 | Feb 26, 2018 |
20. ACTAVIS ELIZABETH
Actavis Elizabeth Llc has filed for 8 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Actavis Elizabeth.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | capsule, extended release | Prescription | ORAL | AB3 | Dec 13, 2018 |
| 5MG | tablet | Discontinued | ORAL | N/A | Feb 5, 2002 |
| 20MG | capsule, extended release | Prescription | ORAL | AB3 | Dec 13, 2018 |
| 30MG | capsule, extended release | Prescription | ORAL | AB3 | Dec 13, 2018 |
| 15MG | capsule, extended release | Prescription | ORAL | AB3 | Dec 13, 2018 |
| 40MG | capsule, extended release | Prescription | ORAL | AB3 | Dec 13, 2018 |
| 50MG | capsule, extended release | Prescription | ORAL | AB3 | Dec 13, 2018 |
| 60MG | capsule, extended release | Prescription | ORAL | AB3 | Dec 13, 2018 |
21. ACCORD HLTHCARE
Accord Healthcare Inc has filed for 3 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet | Prescription | ORAL | AB | Oct 28, 2020 |
| 5MG | tablet | Prescription | ORAL | AB | Oct 28, 2020 |
| 20MG | tablet | Prescription | ORAL | AB | Oct 28, 2020 |
22. SPECGX LLC
Specgx Llc has filed for 10 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Specgx Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG | tablet | Prescription | ORAL | AB | Nov 27, 1998 |
| 20MG | capsule, extended release | Prescription | ORAL | AB2 | Sep 29, 2015 |
| 10MG | capsule, extended release | Prescription | ORAL | AB2 | Sep 29, 2015 |
| 54MG | tablet, extended release | Prescription | ORAL | BX | Dec 28, 2012 |
| 27MG | tablet, extended release | Prescription | ORAL | BX | Dec 28, 2012 |
| 36MG | tablet, extended release | Prescription | ORAL | BX | Dec 28, 2012 |
| 40MG | capsule, extended release | Prescription | ORAL | AB2 | Sep 29, 2015 |
| 50MG | capsule, extended release | Prescription | ORAL | AB2 | Sep 29, 2015 |
| 60MG | capsule, extended release | Prescription | ORAL | AB2 | Sep 29, 2015 |
| 30MG | capsule, extended release | Prescription | ORAL | AB2 | Sep 29, 2015 |
23. BIONPHARMA
Bionpharma Inc has filed for 3 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Bionpharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG | tablet | Prescription | ORAL | AB | Mar 2, 2018 |
| 20MG | tablet | Prescription | ORAL | AB | Mar 2, 2018 |
| 10MG | tablet | Prescription | ORAL | AB | Mar 2, 2018 |
24. ABLE
Able Laboratories Inc has filed for 3 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Able.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG | tablet | Discontinued | ORAL | N/A | Mar 29, 2001 |
| 10MG | tablet | Discontinued | ORAL | N/A | Mar 29, 2001 |
| 20MG | tablet, extended release | Discontinued | ORAL | N/A | May 9, 2001 |
25. MOUNTAIN
Mountain Llc has filed for 3 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Mountain.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 20MG | tablet | Prescription | ORAL | AB | Mar 12, 2014 |
| 5MG | tablet | Prescription | ORAL | AB | Mar 12, 2014 |
| 10MG | tablet | Prescription | ORAL | AB | Mar 12, 2014 |
26. ASCENT PHARMS INC
Ascent Pharmaceuticals Inc has filed for 10 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Ascent Pharms Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG | tablet, chewable | Prescription | ORAL | AB | Dec 29, 2017 |
| 20MG | tablet | Prescription | ORAL | AB | Sep 22, 2015 |
| 10MG
(reference standard) | tablet, chewable | Prescription | ORAL | AB | Dec 29, 2017 |
| 2.5MG | tablet, chewable | Prescription | ORAL | AB | Dec 29, 2017 |
| 18MG | tablet, extended release | Prescription | ORAL | AB | Sep 3, 2019 |
| 27MG | tablet, extended release | Prescription | ORAL | AB | Sep 3, 2019 |
| 36MG | tablet, extended release | Prescription | ORAL | AB | Sep 3, 2019 |
| 54MG | tablet, extended release | Prescription | ORAL | AB | Sep 3, 2019 |
| 10MG/5ML | solution | Prescription | ORAL | AA | Jan 29, 2021 |
| 5MG/5ML | solution | Prescription | ORAL | AA | Jan 29, 2021 |
27. ALVOGEN
Alvogen Inc has filed for 7 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Alvogen.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet | Discontinued | ORAL | N/A | Sep 15, 2016 |
| 20MG | tablet | Discontinued | ORAL | N/A | Sep 15, 2016 |
| 5MG | tablet | Discontinued | ORAL | N/A | Sep 15, 2016 |
| 18MG | tablet, extended release | Discontinued | ORAL | N/A | Nov 30, 2018 |
| 54MG | tablet, extended release | Discontinued | ORAL | N/A | Nov 30, 2018 |
| 36MG | tablet, extended release | Discontinued | ORAL | N/A | Nov 30, 2018 |
| 27MG | tablet, extended release | Discontinued | ORAL | N/A | Nov 30, 2018 |
28. CEDIPROF INC
Cediprof Inc has filed for 3 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Cediprof Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet | Prescription | ORAL | AB | Feb 1, 2019 |
| 20MG | tablet | Prescription | ORAL | AB | Feb 1, 2019 |
| 5MG | tablet | Prescription | ORAL | AB | Feb 1, 2019 |
29. IMPAX LABS INC
Impax Laboratories Inc has filed for 6 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Impax Labs Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | capsule, extended release | Prescription | ORAL | AB2 | Jul 28, 2016 |
| 10MG | capsule, extended release | Prescription | ORAL | AB2 | Jul 28, 2016 |
| 20MG | capsule, extended release | Prescription | ORAL | AB2 | Jul 28, 2016 |
| 30MG | capsule, extended release | Prescription | ORAL | AB2 | Jul 28, 2016 |
| 40MG | capsule, extended release | Prescription | ORAL | AB2 | Jul 28, 2016 |
| 50MG | capsule, extended release | Prescription | ORAL | AB2 | Jul 28, 2016 |
30. PRINSTON INC
Prinston Pharmaceutical Inc has filed for 3 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Prinston Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet | Prescription | ORAL | AB | Jul 23, 2020 |
| 20MG | tablet | Prescription | ORAL | AB | Jul 23, 2020 |
| 5MG | tablet | Prescription | ORAL | AB | Jul 23, 2020 |
31. RHODES PHARMS
Rhodes Pharmaceuticals Lp has filed for 4 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Rhodes Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 18MG | tablet, extended release | Discontinued | ORAL | N/A | May 31, 2022 |
| 27MG | tablet, extended release | Discontinued | ORAL | N/A | May 31, 2022 |
| 36MG | tablet, extended release | Discontinued | ORAL | N/A | May 31, 2022 |
| 54MG | tablet, extended release | Discontinued | ORAL | N/A | May 31, 2022 |
32. ABHAI INC
Abhai Inc has filed for 3 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Abhai Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet | Prescription | ORAL | AB | May 11, 2017 |
| 5MG | tablet | Prescription | ORAL | AB | May 11, 2017 |
| 20MG | tablet | Prescription | ORAL | AB | May 11, 2017 |
33. DR REDDYS
Dr Reddys Laboratories Inc has filed for 4 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 36MG | tablet, extended release | Prescription | ORAL | AB | Jul 29, 2020 |
| 18MG | tablet, extended release | Prescription | ORAL | AB | Jul 29, 2020 |
| 27MG | tablet, extended release | Prescription | ORAL | AB | Jul 29, 2020 |
| 54MG | tablet, extended release | Prescription | ORAL | AB | Jul 29, 2020 |
34. RISING
Rising Pharma Holdings Inc has filed for 3 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Rising.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2.5MG | tablet, chewable | Prescription | ORAL | AB | Nov 7, 2016 |
| 10MG | tablet, chewable | Prescription | ORAL | AB | Nov 7, 2016 |
| 5MG | tablet, chewable | Prescription | ORAL | AB | Nov 7, 2016 |
35. ANI PHARMS
Ani Pharmaceuticals Inc has filed for 4 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Ani Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 54MG | tablet, extended release | Discontinued | ORAL | N/A | Jul 14, 2017 |
| 18MG | tablet, extended release | Discontinued | ORAL | N/A | Jul 14, 2017 |
| 36MG | tablet, extended release | Discontinued | ORAL | N/A | Jul 14, 2017 |
| 27MG | tablet, extended release | Discontinued | ORAL | N/A | Jul 14, 2017 |
36. CHARTWELL MOLECULAR
Chartwell Molecular Holdings Llc has filed for 2 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Chartwell Molecular.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG/5ML | solution | Discontinued | ORAL | N/A | Dec 16, 2020 |
| 10MG/5ML | solution | Discontinued | ORAL | N/A | Dec 16, 2020 |
37. TEVA PHARMS
Teva Pharmaceuticals Usa has filed for 6 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Teva Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | capsule, extended release | Prescription | ORAL | AB2 | Jul 19, 2012 |
| 30MG | capsule, extended release | Prescription | ORAL | AB2 | Jul 19, 2012 |
| 20MG | capsule, extended release | Prescription | ORAL | AB2 | Jul 19, 2012 |
| 10MG | capsule, extended release | Prescription | ORAL | AB2 | Jul 19, 2012 |
| 40MG | capsule, extended release | Prescription | ORAL | AB2 | Jul 19, 2012 |
| 50MG | capsule, extended release | Prescription | ORAL | AB2 | Jul 19, 2012 |
38. BARR LABS INC
Barr Laboratories Inc has filed for 4 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Barr Labs Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 20MG | capsule, extended release | Discontinued | ORAL | N/A | Jul 13, 2012 |
| 30MG | capsule, extended release | Discontinued | ORAL | N/A | Jul 13, 2012 |
| 40MG | capsule, extended release | Discontinued | ORAL | N/A | Jul 13, 2012 |
| 10MG | capsule, extended release | Discontinued | ORAL | N/A | Oct 15, 2014 |
39. BRECKENRIDGE
Breckenridge Pharmaceutical Inc has filed for 2 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Breckenridge.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG/5ML | solution | Discontinued | ORAL | N/A | Nov 12, 2013 |
| 10MG/5ML | solution | Discontinued | ORAL | N/A | Nov 12, 2013 |
40. ALKEM LABS LTD
Alkem Laboratories Ltd has filed for 9 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Alkem Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet | Prescription | ORAL | AB | Oct 4, 2019 |
| 20MG | tablet, extended release | Prescription | ORAL | AB | Oct 6, 2020 |
| 5MG | tablet | Prescription | ORAL | AB | Oct 4, 2019 |
| 5MG/5ML | solution | Prescription | ORAL | AA | Mar 30, 2020 |
| 10MG/5ML | solution | Prescription | ORAL | AA | Mar 30, 2020 |
| 27MG | tablet, extended release | Prescription | ORAL | AB | May 23, 2023 |
| 36MG | tablet, extended release | Prescription | ORAL | AB | May 23, 2023 |
| 54MG | tablet, extended release | Prescription | ORAL | AB | May 23, 2023 |
| 18MG | tablet, extended release | Prescription | ORAL | AB | May 23, 2023 |
41. GRANULES
Granules Pharmaceuticals Inc has filed for 5 different strengths of generic version for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Granules.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 20MG | capsule, extended release | Prescription | ORAL | AB1 | May 23, 2019 |
| 10MG | capsule, extended release | Prescription | ORAL | AB1 | May 23, 2019 |
| 40MG | capsule, extended release | Prescription | ORAL | AB1 | May 23, 2019 |
| 30MG | capsule, extended release | Prescription | ORAL | AB1 | May 23, 2019 |
| 60MG | capsule, extended release | Prescription | ORAL | AB1 | May 23, 2019 |
42. ACTAVIS LABS FL INC
Actavis Laboratories Fl Inc has filed for 1 generic for Methylphenidate Hydrochloride. Given below are the details of the strengths of this generic introduced by Actavis Labs Fl Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG/ML | for suspension, extended release | Prescription | ORAL | AB | May 17, 2018 |